Month-by-month projection of where your weight lands on semaglutide, tirzepatide or liraglutide, built from the published trial curves.
Pick "typical" if you are just starting out. Trial averages hide a wide spread, so this is a range, not a promise.
| Month | Projected weight | Total lost | % of body weight |
|---|
The curve is fitted to the average total body weight reduction reported in the major randomised trials, then scaled to your starting weight:
Loss is front-loaded and flattens. The curve reflects that, which is why the first two months look fast and month ten looks nearly flat. That flattening is expected, not a sign something broke.
Trial averages are averages. In SURMOUNT-1 some participants lost over 30% of their body weight and some lost under 5% on the same dose. A projection is a planning tool for setting expectations, not a forecast of your individual result.
It also assumes you reach and stay on a maintenance dose, stay on the medication continuously, and do not have a supply gap. Interruptions change the curve more than almost anything else.
And it says nothing about body composition. Losing weight without protecting muscle is a worse outcome at the same number on the scale. Protein intake and resistance training are what separate the two.
GLPme logs every shot, remembers your titration schedule, warns you before you run out of medication, and shows your weight trend against your goal. Core tracking is free.